



Announces a Live & Interactive Telephone Symposium Series

MODERATOR

Prakash S. Masand, M.D.

Professor of Psychiatry
Department of Psychiatry
SUNY Upstate Medical University
Syracuse, NY

Register for the session that is most convenient for you!

By Phone: Call IMN at 888-466-3250, x1

Dates	ET	CT	MT	PT
11/6/00	1:00P	12:00P	11:00A	10:00A
11/7/00	12:00P	11:00A	10:00A	9:00A
11/10/00	12:00P	11:00A	10:00A	9:00A
11/13/00	3:00P	2:00P	1:00P	12:00P
11/20/00	1:00P	12:00P	11:00A	10:00A
12/7/00	8:00P	7:00P	6:00P	5:00P
12/11/00	12:00P	11:00A	10:00A	9:00A
12/11/00	3:00P	2:00P	1:00P	12:00P
12/20/00	1:00P	12:00P	11:00A	10:00A
12/21/00	12:30P	11:30A	10:30A	9:30A

This activity was supported by an unrestricted educational grant from AstraZeneca.

For more information or to register, please call IMN at: 888-466-3250 or visit www.psychlink.pwpl.com and follow the link for psychLINK OnCall.



INTERACTIVE MEDICAL NETWORKS

a division of PRIMEDIA Healthcare

Novel Antipsychotics: Schizophrenia and Beyond

Also archived on the Internet:

www.psychlink.pwpl.com

(Available late November 2000)

STATEMENT OF NEED

Novel antipsychotics have surpassed conventional neuroleptics as first-line agents for the treatment of schizophrenia and several nonschizophrenic conditions. They offer a comparable efficacy profile and superior safety and tolerability profile with respect to extrapyramidal symptoms (EPS and tardive dyskinesia) as compared to the conventional neuroleptics. Within the class of novel antipsychotics, agents differ in terms of dosing regimens and side effect profiles. Clinicians are finding uses for this class of drugs not only for schizophrenia, but for several non-psychotic disorders such as bipolar disorder, dementia, aggressivity, anxiety disorders (particularly obsessive compulsive disorder and posttraumatic stress disorder), neurodegenerative disorders including Parkinson's disease, delirium and personality disorder. The audioconference will explore the use of the novel antipsychotics in the treatment of schizophrenia as well as non-psychotic disorders.

LEARNING OBJECTIVES

Upon completion of this activity, the participant should be able to:

- Review the evidence for the efficacy and dosing of novel antipsychotics in schizophrenia and non-psychotic disorders.
- Speculate about the mechanisms that may contribute to the efficacy of novel antipsychotics in these conditions.
- Compare the tolerability and side effect profile of the novel antipsychotics relative to the conventional neuroleptics and compared to each other.

TARGET AUDIENCE

Physicians, pharmacists and psychiatric nurses.

Credit Information

Successful completion of this CE activity includes the following:

- Attend a live telephone symposium or complete the internet archive activity.
- Complete the appropriate CE application and activity evaluation form. Excluding physicians, participants viewing the recorded activity must complete the post-test.
- Submit forms to the address indicated for processing.

Participants will receive a CE statement of credit within 4 weeks following receipt of the CE application and activity evaluation form. There is no fee for participation in this activity.

PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. PRIMEDIA Healthcare designates this educational activity for a maximum of 1.0 hour(s) in Category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. This CME activity was planned and produced in accordance with the ACCME Essentials.

This activity for 1.2 contact hours is provided by PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation. Accreditation by the American Nurses Credentialing Center's Commission on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

PRIMEDIA Healthcare, a division of PRIMEDIA Workplace Learning, is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education.

ACPE Credit: 1.0 Contact Hours or 0.10 CEUs

Universal Program Number: 775-000-00-048-L01 (live presentation)

775-000-00-048-H01 (internet archive self study)

